Filtered By:
Condition: Thrombosis
Drug: Plavix
Procedure: Coronary Angioplasty
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 154 results found since Jan 2013.
Impact of Transcatheter Aortic Valve Implantation on Thrombin Generation and Platelet Function
CONCLUSION: In this pilot study, we were able to demonstrate that thrombin generation is significantly increased early after TAVI, while platelet function is not affected. Increased thrombin concentrations may contribute to the high risk of postprocedural thromboembolic events. This leads to the hypothesis that extended peri-interventional anticoagulation early after TAVI may be an approach to reduce thromboembolic events.PMID:33759144 | DOI:10.1055/s-0041-1725190
Source: Thrombosis and Haemostasis - March 24, 2021 Category: Hematology Authors: Philipp Mourikis Lisa Dannenberg Saif Zako Carolin Helten Ren é M'Pembele Hannah Richter Thomas Hohlfeld Christian Jung Tobias Zeus Malte Kelm Verena Veulemans Amin Polzin Source Type: research
Reduced-Dose Prasugrel versus Clopidogrel for Patients Undergoing Percutaneous Coronary Intervention
Int Heart J. 2021 Mar 17. doi: 10.1536/ihj.20-508. Online ahead of print.ABSTRACTWhether reduced-dose prasugrel has a better efficacy or safety than standard-dose clopidogrel remains unknown in patients undergoing percutaneous coronary intervention (PCI).A systematic search of PubMed, EMBASE, Google Scholar, and Cochrane Library from database inception to May 1, 2020 was performed to compare the clinical outcomes in patients with acute coronary syndrome or stable coronary artery disease undergoing PCI between those treated with reduced-dose prasugrel and clopidogrel. The pooled odds ratio (OR) and 95% confidence interval (...
Source: International Heart Journal - March 18, 2021 Category: Cardiology Authors: Cheng-Han Lee Mu-Shiang Huang Ting-Hsing Chao Sheng-Hsiang Lin Yi-Heng Li Source Type: research
Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis
ConclusionStable CAD patients treated with clopidogrel and carriedCYP2C19 LoF alleles undergoing PCI were associated with significantly increased risk of MACE compared to non-carriers, even markedly significant for Asian patients.
Source: Cardiovascular Drugs and Therapy - February 1, 2021 Category: Cardiology Source Type: research
Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes
Clopidogrel, prasugrel, and ticagrelor are oral platelet P2Y12 receptor inhibitors that decrease the risk of platelet-mediated coronary artery thrombosis. Clinical guidelines have recommended ticagrelor or prasugrel over clopidogrel in combination with aspirin as dual antiplatelet therapy (DAPT) for 1 year after acute coronary syndrome (ACS), whether or not percutaneous coronary intervention (PCI) is performed. The ticagrelor recommendation was based on the Study of Platelet Inhibition and Patient Outcomes (PLATO) trial, which enrolled 18 624 patients with ACS and randomized them to receive DAPT with either clopidogrel ...
Source: JAMA - October 27, 2020 Category: General Medicine Source Type: research
Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
CONCLUSIONS: Ticagrelor was associated with a lower incidence of MACCEs without an increased risk of bleeding events in patients with SCAD receiving PCI.
PMID: 32908113 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 12, 2020 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
CONCLUSIONS: Among patients with theCYP2C19LOF allele, the use of clopidogrel was significantly associated with increased adverse events. Thus, further investigation is needed to establish the practical use ofCYP2C19genotyping.
PMID: 32713878 [PubMed - as supplied by publisher]
Source: Circulation Journal - July 20, 2020 Category: Cardiology Authors: Sawayama Y, Yamamoto T, Tomita Y, Asada K, Yagi N, Fukuyama M, Miyamoto A, Sakai H, Ozawa T, Isono T, Hira D, Terada T, Horie M, Nakagawa Y Tags: Circ J Source Type: research
